| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Access to innovative oncology medicines in Europe
|
Bergmann, L.
|
|
|
27 |
2 |
p. 353-356
|
artikel
|
| 2 |
A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma
|
Rosati, G.
|
|
|
27 |
2 |
p. 274-280
|
artikel
|
| 3 |
Beyond the exome: the role of non-coding somatic mutations in cancer
|
Piraino, S.W.
|
|
|
27 |
2 |
p. 240-248
|
artikel
|
| 4 |
Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes
|
Laurent, C.
|
|
|
27 |
2 |
p. 306-314
|
artikel
|
| 5 |
Can ovarian suppression with gonadotropin-releasing hormone analogs (GnRHa) preserve fertility in cancer patients?
|
Rodriguez-Wallberg, K.
|
|
|
27 |
2 |
p. 357
|
artikel
|
| 6 |
Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies
|
Postel-Vinay, S.
|
|
|
27 |
2 |
p. 214-224
|
artikel
|
| 7 |
Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer
|
Pruneri, G.
|
|
|
27 |
2 |
p. 249-256
|
artikel
|
| 8 |
Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV
|
Lévi, F.A.
|
|
|
27 |
2 |
p. 267-274
|
artikel
|
| 9 |
Correction to: Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis
|
Bracarda, S.
|
|
|
27 |
2 |
p. 366
|
artikel
|
| 10 |
Editorial Board
|
|
|
|
27 |
2 |
p. ii-iii
|
artikel
|
| 11 |
Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL
|
Graff, J.N.
|
|
|
27 |
2 |
p. 286-294
|
artikel
|
| 12 |
Environmental emissions, public health and lung cancer risk
|
Swanton, C.
|
|
|
27 |
2 |
p. 211-212
|
artikel
|
| 13 |
Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance) †
|
Yoon, H.H.
|
|
|
27 |
2 |
p. 339-344
|
artikel
|
| 14 |
Guidelines for endometrial cancer management: finding order amid the uncertainties
|
Eifel, P.J.
|
|
|
27 |
2 |
p. 212-213
|
artikel
|
| 15 |
Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study
|
Lassalle, A.
|
|
|
27 |
2 |
p. 314-318
|
artikel
|
| 16 |
In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium
|
Lobbezoo, D.J.A.
|
|
|
27 |
2 |
p. 256-262
|
artikel
|
| 17 |
KRT81 miR-SNP rs3660 is associated with risk and survival of NSCLC
|
Robles, A.I.
|
|
|
27 |
2 |
p. 360-361
|
artikel
|
| 18 |
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort
|
Mazières, J.
|
|
|
27 |
2 |
p. 281-286
|
artikel
|
| 19 |
More colors to the palette
|
Bracarda, S.
|
|
|
27 |
2 |
p. 363
|
artikel
|
| 20 |
Next-generation sequencing of the basal cell carcinoma miRNome and a description of novel microRNA candidates under neoadjuvant vismodegib therapy: an integrative molecular and surgical case study
|
Sand, M.
|
|
|
27 |
2 |
p. 332-338
|
artikel
|
| 21 |
Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer †
|
Mitsuhashi, A.
|
|
|
27 |
2 |
p. 262-266
|
artikel
|
| 22 |
Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors
|
Wong, S.J.
|
|
|
27 |
2 |
p. 318-323
|
artikel
|
| 23 |
Pre-treatment lymphocytopaenia is an adverse prognostic biomarker in muscle-invasive and advanced bladder cancer †
|
Joseph, N.
|
|
|
27 |
2 |
p. 294-299
|
artikel
|
| 24 |
Prevalence of rare EGFR gene mutations in nonsmall-cell lung cancer: a multicenter study on 3856 Polish Caucasian patients
|
Krawczyk, P.
|
|
|
27 |
2 |
p. 358-359
|
artikel
|
| 25 |
Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors
|
Cierna, Z.
|
|
|
27 |
2 |
p. 300-305
|
artikel
|
| 26 |
Reply to ‘Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance’ by Funck-Brentano et al.
|
Goldwirt, L.
|
|
|
27 |
2 |
p. 363-364
|
artikel
|
| 27 |
Reply to the letter to the editor ‘KRT81 miR-SNP rs3660 is associated with risk and survival of NSCLC’ by Robles et al.
|
Lee, S.Y.
|
|
|
27 |
2 |
p. 361-363
|
artikel
|
| 28 |
Reply to the letter to the editor ‘Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumor response and tolerance’ by Funck-Brentano et al.
|
Funck-Brentano, E.
|
|
|
27 |
2 |
p. 364-365
|
artikel
|
| 29 |
Reply to the letter to the editor ‘Prevalence of rare EGFR mutations in non-small cell lung cancer: a multicenter study on 3856 Polish Caucasian patients’ by Krawczyk et al.
|
Beau-Faller, M.
|
|
|
27 |
2 |
p. 359-360
|
artikel
|
| 30 |
Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?
|
Postel-Vinay, S.
|
|
|
27 |
2 |
p. 344-352
|
artikel
|
| 31 |
Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer
|
Donnem, T.
|
|
|
27 |
2 |
p. 225-232
|
artikel
|
| 32 |
Table of Contents
|
|
|
|
27 |
2 |
p. iv-vi
|
artikel
|
| 33 |
The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MO S AIC, a multicenter cluster-randomized phase III study (SAKK 95/06)
|
Strasser, F.
|
|
|
27 |
2 |
p. 324-332
|
artikel
|
| 34 |
Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics
|
Dimopoulos, M.A.
|
|
|
27 |
2 |
p. 233-240
|
artikel
|
Tijdschrift beschrijving